Chiesi is one of the top 50 pharmaceutical companies globally, with over 90 years of experience transforming patient care through innovative therapeutic solutions. Headquartered in Parma, Italy, this research-oriented international biopharmaceutical group employs more than 8,000 people across 31 countries, united by a singular purpose: promoting a healthier world for people, patients, and the planet. As a family-owned company now in its third generation, Chiesi has developed expertise in respiratory health, neonatology, special care, and rare diseases - touching millions of lives through groundbreaking medicines and treatments.
In 2019, Chiesi became the world's largest pharmaceutical group certified as a B Corp, demonstrating its commitment to meeting high standards of social and environmental performance. The company operates as a Benefit Corporation, embedding sustainability directly into its bylaws and continuously measuring its impact on patients, the planet, and communities. With over €3 billion in global sales and a 10% year-over-year growth, Chiesi has established itself as a leader in biotech innovation, including opening a state-of-the-art Biotech Center of Excellence in 2024. Their pipeline spans lysosomal storage diseases, rare hematology, ophthalmology disorders, and rare immunodeficiencies, ensuring that no patient is left behind.